Introduction
============

According to "the World Health Report 2001" by the World Health Organization, approximately one in ten persons suffer from depression globally, and depression is expected to become the second most common disease after coronary heart disease in 2020. The incidence of depression in the People's Republic of China is estimated at 5%--6% of the population[@b1-ndt-12-1715] compared to 15.4% in the US[@b2-ndt-12-1715] and 27% in European countries.[@b3-ndt-12-1715] The total number of depression patients in the People's Republic of China has reached 90 million[@b1-ndt-12-1715] and continues to rise, compromising the health of the general population. Depression has a long treatment cycle period, slow efficacy of medications, and high recurrence rate.

Fluoxetine, paroxetine, sertraline, citalopram, escitalopram, and fluvoxamine are the most commonly used selective serotonin reuptake inhibitors (SSRIs) for treatment of major depression. However, these antidepressants may cause multiple side effects, such as nausea, insomnia, and sexual dysfunction.[@b4-ndt-12-1715] Thirty-eight percent of patients with long-term use of SSRIs have experienced at least one side effect, with sexual dysfunction, sleepiness, and weight gain being the most common.[@b5-ndt-12-1715]

Well-defined extracts from St John's wort (*Hypericum perforatum*), namely, St John's wort extract (Neurostan), have been used to treat depression for more than a 100 years in Germany. Significant efficacy and safety have been demonstrated in animal studies and clinical trials.[@b6-ndt-12-1715],[@b7-ndt-12-1715] St John's wort has better antidepressant efficacy than placebo[@b8-ndt-12-1715]--[@b10-ndt-12-1715] and lower rates of side effects than conventional antidepressants.[@b11-ndt-12-1715],[@b12-ndt-12-1715] The use of St John's wort extract for patients with depression, however, remains somewhat controversial, since some studies showed no significant difference in efficacy and safety between St John's wort extract and conventional SSRIs.[@b11-ndt-12-1715]--[@b15-ndt-12-1715] Given that depression often requires rapid, timely, and prolonged treatment, we should consider not only the effectiveness but also safety of the treatment. Therefore, based on the meta-analysis by Rahimi et al,[@b16-ndt-12-1715] which covers literature from 1966 to June 2008, we collected published randomized, controlled clinical trials comparing the efficacy and safety of St John's wort extract and SSRIs from June 2008 to April 2015. In addition, we included similar studies that have been published since 1966 in the People's Republic of China to conduct a comprehensive and objective update on the use of St John's wort extract as an alternative to SSRIs.

Materials and methods
=====================

Data sources
------------

The search terms were "St John's wort" or "hypericum" or "Neurostan" and "fluoxetine" or "paroxetine" or "citalopram" or "sertraline" or "escitalopram" or "fluvoxamine" and "depression." PubMed, Cochrane Central Register of Controlled Trials, and Ovid Technologies were searched from June 2008 to April 2015, and China Biology Medicine disc, WanFang Data, and China National Knowledge Infrastructure were searched from 1966 to April 2015.

Study selection
---------------

We searched for studies of treatment of depression with St John's wort extract with no language restriction. All studies were required to meet the following inclusion criteria: 1) randomized controlled trials, 2) depressive patients, 3) at least 4 weeks of treatment, 4) SSRI-controlled, 5) available efficacy or safety indicators, and 6) outcome measures for depression or clinical diagnosis. Exclusion criteria were as follows: 1) lack of data on efficacy and safety, 2) combination with other antidepressants, and 3) single-blind and uncontrolled trials. Data from selected studies were extracted in tabular form, including basic information on the study, study design, study time, intervention measures, and specific outcomes.

Measures of efficacy and safety
-------------------------------

The primary outcome measure for treatment efficacy and safety was change in total Hamilton Rating Scale for Depression (HAMD) score between baseline and end point. Responder rates (reduction in HAMD score \>50%), remission rate (reduction in HAMD score \>75%), mean reduction in HAMD score, the incidence of adverse events, total withdrawal rate, and withdrawals due to adverse events were the key outcomes of interest.

Formula conversion
------------------

Some of the data in this study were not directly usable for statistical analysis, and therefore, converted into a form available for analysis. The main formulas used were 1) calculation of mean and standard deviation (SD) for change according to the known mean and SD before and after treatment: mean (*b* -- *a*) = mean (*b*) -- (*a*), variance (*b* -- *a*) = variance (*b*) + variance (*a*), taking the square root to obtain SD: (*b* -- *a*) and 2) calculation of SD: (CI~max~ -- CI~min~)/(1.96×2) by using the confidence intervals.

Statistical analysis
--------------------

All included studies were analyzed using Stata/SE (11.2) (StataCorp LP, College Station, TX, USA). For each meta-analysis, heterogeneity of treatment effects was tested before the data were pooled; if *P*\>0.05 or *I*^2^\<50%, we considered the data to be homogeneous and used a fixed-effects model. Otherwise, we applied a random-effects model. Relative risk (RR) and 95% confidence intervals (95% CI) were calculated, and effect size (weighted mean difference) meta-analysis was performed. The event rate in the experimental (intervention) group against the event rate in the control group was calculated using the chi-square test, and the results were expressed as an odds ratio (OR) and *P*-values.

Results
=======

A total of 27 articles were retrieved.[@b11-ndt-12-1715]--[@b15-ndt-12-1715],[@b17-ndt-12-1715]--[@b24-ndt-12-1715] The basic data of all studies are shown in [Table 1](#t1-ndt-12-1715){ref-type="table"}. A total of 3,126 patients were included in the analysis, with 1,177 patients from the People's Republic of China.

Efficacy
--------

Summary RR for all included studies for clinical response was 1.02 (95% CI: 0.96, 1.09, *P*=0.51, [Figure 1](#f1-ndt-12-1715){ref-type="fig"}). Furthermore, the combined summary RR of all studies for remission by St John's wort extract versus SSRIs therapy was 1.07 (95% CI: 0.94, 1.22, *P*=0.308, [Figure 2](#f2-ndt-12-1715){ref-type="fig"}). Effect size (standard mean difference) for mean reduction in HAMD score from baseline with St John's wort extract versus SSRIs therapy among all the studies was −0.06 (95% CI: −0.13, 0.02, *P*=0.15, [Figure 3](#f3-ndt-12-1715){ref-type="fig"}).

Safety
------

The number of patients reporting adverse events and withdrawal due to adverse events were evaluated in 19 and 12 trials, respectively. The summary RR for adverse events of St John's wort extract versus SSRI therapy among all included trials was 0.77 (95% CI: 0.70, 0.84, *P*=0.00) ([Figure 4](#f4-ndt-12-1715){ref-type="fig"}). Twelve trials investigated withdrawals and withdrawal due to adverse events of St John's wort extract and SSRI therapy. The total withdrawal rate and withdrawal rate due to adverse events were 18.2% (167/916) and 4.1% (38/916) in the St John's wort extract group, and 20.3% (183/901) and 6.7% (61/901) in the SSRI group, respectively. There was no significant difference in the total withdrawal rate of the two groups (chi-square test; OR =0.88, 95% CI: 0.69, 1.11, *P*=0.28). Withdrawal due to adverse events in the St John's wort extract group was significantly less than that in the SSRI group (OR =0.60, 95% CI: 0.39, 0.90, *P*=0.02).

Publication bias
----------------

We did not observe a skewed distribution and the data substantially met a normal distribution, and the publication bias was also small.

Sensitivity analysis
--------------------

We excluded trials one by one to perform sensitivity analysis. There was no significant difference between the statistical results before and after each exclusion, indicating that the study was stable and reliable.

Discussion
==========

Although St John's wort extract has been used to treat depression for \>100 years and its efficacy[@b8-ndt-12-1715]--[@b10-ndt-12-1715] and safety[@b11-ndt-12-1715],[@b12-ndt-12-1715] have been proven in several clinical studies, its use in depression still remains somewhat controversial. A meta-analysis by Rahimi et al[@b16-ndt-12-1715] of 13 eligible randomized, placebo-controlled clinical trials published between 1966 and 2008 showed that St John's wort extract was comparable to SSRIs in efficacy and safety. Our current meta-analysis included additional studies as of 2008 with a total of 27 eligible studies and 3,126 depression patients. We found that consistent with the findings of Rahimi et al,[@b16-ndt-12-1715] St John's wort extract was comparable to SSRIs in efficacy, including clinical response, remission, and mean reduction in HAMD score. Unlike the study by Rahimi et al,[@b16-ndt-12-1715] we further demonstrated that St John's wort extract had a lower incidence of adverse events than SSRIs. These findings indicate that, compared to SSRIs, St John's wort extract is equally effective, but has superior safety in the management of depression patients.

St John's wort extract is currently the only pure plant antidepressant and is especially suitable for mild-to-moderate depression. It competitively inhibits absorption of serotonin, noradrenaline, and dopamine; it also downregulates presynaptic membrane-adrenergic receptor density and reduces binding of neurotransmitters to presynaptic membrane-adrenergic receptors, thereby increasing their concentrations in the synaptic cleft, mimicking the effect of antidepressants.[@b25-ndt-12-1715],[@b26-ndt-12-1715] Studies have shown that St John's wort extract is superior to placebo[@b8-ndt-12-1715]--[@b10-ndt-12-1715] and comparable to SSRIs[@b27-ndt-12-1715] in efficacy. St John's wort causes mild adverse effects such as occasional dry mouth and constipation, and it causes no memory impairment, an apparent advantage for older patients.[@b28-ndt-12-1715] Our study demonstrates significantly lower rates of adverse events in depression patients receiving St John's wort extract versus SSRIs, and consistent with the study by Rahimi et al,[@b16-ndt-12-1715] markedly lower rates of withdrawal due to adverse events.

One limitation of the current meta-analysis is the lack of data on treatment of adolescents with depression. Depression is a significant disease for adolescents. Little literature has been published on adolescent depression. All studies included in our meta-analysis involve only adult patients with depression. A small number of studies have shown that St John's wort extract is superior to placebo in treating teenagers with moderate and severe depression;[@b29-ndt-12-1715],[@b30-ndt-12-1715] however, a definite conclusion awaits the results of randomized controlled trials involving a larger population of adolescents with depression. Depression is a chronic disease requiring long-term medication therapy, incurring a financial burden on the patients. It is also important to investigate cost-effectiveness of St John's wort extract versus SSRIs, which was not addressed in our meta-analysis. Solomon et al[@b31-ndt-12-1715] investigated the economic cost of St John's wort extract for mild-to-moderate depression using Markov model and found that St John's wort extract markedly reduced medication costs compared with SSRIs.

Conclusion
==========

Although St John's wort has been used as a herbal remedy for depression for many years, especially in Germany and other European countries, its efficacy is still controversial. Our meta-analysis analyzed 27 studies and 3,126 depression patients and so far represents the most comprehensive analysis of clinical studies on St John's wort for depression. Although this study did not explore neurobiological mechanisms of St John's wort, our results are consistent with the hypothesis that St John's wort is an effective therapy for depression. Furthermore, our analysis demonstrates that in the treatment of depression, especially mild-to-moderate depression, St John's wort extract has comparable efficacy to SSRIs, while the rate of adverse events and withdrawals is significantly lower than that of traditional SSRIs. Given the low cost of treatment with St John's wort extract versus SSRIs, its significant efficacy, and good safety profile, St John's wort extract may be a preferred therapeutic choice in the management of depression.
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![Pooled relative risk of the outcome of "clinical response" in the studies comparing St John's wort extract versus SSRIs therapy.\
**Abbreviations:** CI, confidence interval; RR, relative risk; SSRIs, selective serotonin reuptake inhibitors.](ndt-12-1715Fig1){#f1-ndt-12-1715}

![Pooled relative risk of the outcome of "remission" in the studies comparing St John's wort extract versus SSRI therapy.\
**Abbreviations:** CI, confidence interval; RR, relative risk; SSRIs, selective serotonin reuptake inhibitors.](ndt-12-1715Fig2){#f2-ndt-12-1715}

![Pooled standard mean difference for the outcome of "mean reduction in HAMD score from baseline" in the studies comparing St John's wort extract versus SSRI therapy.\
**Abbreviations:** CI, confidence interval; HAMD, Hamilton Rating Scale for Depression; SMD, standard mean difference; SSRIs, selective serotonin reuptake inhibitors.](ndt-12-1715Fig3){#f3-ndt-12-1715}

![Pooled relative risk of the outcome of "adverse events" in the studies comparing St John's wort extract versus SSRI therapy.\
**Abbreviations:** CI, confidence interval; RR, relative risk; SSRIs, selective serotonin reuptake inhibitors.](ndt-12-1715Fig4){#f4-ndt-12-1715}

###### 

Characteristics of studies included in the meta-analysis

  Study                                  Setting                                          Original country             Participants                        Hypericum preparation                   SSRI                                     Diagnosis criteria   Depression severity       Indicators                                      N     Jadad score
  -------------------------------------- ------------------------------------------------ ---------------------------- ----------------------------------- --------------------------------------- ---------------------------------------- -------------------- ------------------------- ----------------------------------------------- ----- -------------
  Harrer et al[@b17-ndt-12-1715]         Randomized double-blind comparative trial        Germany                      Psychiatric disorders               LoHyp-57 (800 mg/d for 6 weeks)         Fluoxetine (20 mg/d for 6 weeks)         ICD-10               Mild to moderate          Clinical response, HAMD, AD                     161   3
  Brenner et al[@b18-ndt-12-1715]        Randomized, controlled, blinded                  USA                          Depressive disorder                 LI-160 (600--900 mg/d for 7 weeks)      Sertraline (50--75 mg/d for 7 weeks)     DSM-IV               Mild to moderate          HAMD, Clinical Global Impression                30    3
  Schrader[@b19-ndt-12-1715]             Randomized, controlled, double-blind             Germany                      Depressive disorder                 Ze117 (500 mg/d for 6 weeks)            Fluoxetine (20 mg for 6 weeks)           ICD-10               Mild to moderate          HAMD, Clinical Global Impression                240   4
  Behnke et al[@b20-ndt-12-1715]         Randomized, controlled, double-blind             Denmark                      Depressive disorder                 Calmigen (300 mg/d for                  Fluoxetine (40 mg/d for 6 weeks)         ICD-10               Mild to moderate          HAMD, Clinical Global Impression                70    3
  Hypericum Depression                   Double-blind, randomized                         USA                          Major depression disorder           LI-160 (900--1,500 mg/d for 8 weeks)    Sertraline (50--100 mg/d for 8 weeks)    DSM-IV               Moderate to severe        HAMD, adverse effect                            428   5
  van Gurp et al[@b22-ndt-12-1715]       Double-blind, randomized                         Canada                       Major depression                    SJW (900--1,800 mg/d for 12 weeks)      Sertraline (50--100 mg/d for 12 weeks)   DSM-IV               Mild to severe            HAMD, self-reported side effects                90    4
  Bjerkenstedt et al[@b23-ndt-12-1715]   Randomized, placebo-controlled multicenter       Germany                      Major depression disorder           LI-160 (900 mg/d for 4 weeks)           Fluoxetine (20 mg/d for 4 weeks)         DSM-IV               Mild or moderate          HAMD, safety and tolerability                   174   3
  Gastpar et al[@b13-ndt-12-1715]        Randomized, double-blind                         Germany                      Moderate depression                 STW3 (612 mg/d for 12 weeks)            Sertraline (50 mg/d for 12 weeks)        ICD-10               Moderate                  HAMD, adverse events                            241   4
  Fava et al[@b11-ndt-12-1715]           Randomized, parallel-group, double-blind study   Germany                      Major depressive disorder           LI-160 (900 mg/d for 12 weeks)          Fluoxetine (20 mg/d for 12 weeks)        DSM-IV               Mild to severe            HAMD, CGI-I, adverse events                     135   4
  Szegedi et al[@b12-ndt-12-1715]        Randomized, double-blind                         Germany                      Acute major depression              WS 5570 (900--1,800 mg/d for 6 weeks)   Paroxetine (20--40 mg/d for 6 weeks)     DSM-IV               Moderate                  HAMD, adverse events                            301   5
  Gastpar et al[@b14-ndt-12-1715]        Randomized, double-blind                         Germany                      Moderate depression                 STW3-VI (900 mg/d for 6 weeks)          Citalopram (20 mg/d for 6 weeks)         ICD-10               Moderate                  HAMD, responders, adverse events                388   5
  Moreno et al[@b15-ndt-12-1715]         Randomized, double-blind                         wBrazil                      Affective disorders of psychiatry   Iperisan (900 mg/d for 8 weeks)         Fluoxetine (20 mg/d for 8 weeks)         DSM-IV               Mild to moderate          HAMD, Clinical Global Impression                72    3
  Papakostas et al[@b24-ndt-12-1715]     Randomized, parallel-group, double-blind study   USA                          Major depressive disorder           LI-160 (20 mg/d for 12 weeks)           Fluoxetine (20 mg/d for 12 weeks)        DSM-IV               Mild to severe            Response, remission, HDRS-17 scores             135   2
  Rapaport et al[@b44-ndt-12-1715]       Three-arm, randomized clinical trial             USA                          Minor depression                    SJW (810 mg/d for 12 weeks)             Citalopram (20 mg/d for 12 weeks)        DSM-IV               Mild                      HAMD, adverse events                            169   3
  Gu et al[@b32-ndt-12-1715]             Randomized, double-blind, multicenter            People's Republic of China   Depressive disorder                 SJW (900 mg/d for 6 weeks)              Fluoxetine (20 mg/d for 6 weeks)         CCMD-2-R             Mild to moderate          HAMD, HAMA, adverse events                      135   4
  Mo et al[@b33-ndt-12-1715]             Randomized, double-blind                         People's Republic of China   Post-stroke depression              SJW (1,350 mg/d for 7 weeks)            Fluoxetine (20 mg/d for 6 weeks)         CCMD-2-R(3)          HAMD total score 18--24   HAMD, clinical response, adverse events         65    3
  Wang et al[@b34-ndt-12-1715]           Randomized, open                                 People's Republic of China   Depressive disorder                 SJW (900 mg/d for 6 weeks)              Fluoxetine (20 mg/d for 6 weeks)         CCMD-3               HAMD total score 18--24   HAMD, HAMA, adverse events                      40    2
  Zhang et al[@b35-ndt-12-1715]          Randomized, controlled                           People's Republic of China   Depressive disorder                 SJW (900 mg/d for 6 weeks)              Paroxetine (20 mg/d for 6 weeks)         CCMD-3               HAMD total score ≥18      HAMD, HAMA, clinical response, adverse events   56    2
  Gao[@b36-ndt-12-1715]                  Controlled                                       People's Republic of China   Post-stroke depression              SJW (600 mg/d for 4 weeks)              Paroxetine (20 mg/d for 4 weeks)         Unknown              HAMD total score ≥18      HAMD, HAMA, clinical response, adverse events   68    1
  Lou et al[@b37-ndt-12-1715]            Randomized, open, controlled                     People's Republic of China   Depressive disorder                 SJW (900 mg/d for 7 weeks)              Fluoxetine (20 mg/d for 7 weeks)         CCMD-3               HAMD total score ≥18      HAMD, HAMA, clinical response, adverse events   81    2
  Hu et al[@b38-ndt-12-1715]             Randomized, open, controlled                     People's Republic of China   Depressive disorder                 SJW (900 mg/d for 6 weeks)              Paroxetine (20 mg/d for 6 weeks)         CCMD-3               HAMD total score ≥18      HAMD, HAMA, clinical response, adverse events   70    2
  Hu and Yang[@b39-ndt-12-1715]          Randomized, open, controlled                     People's Republic of China   Depressive disorder                 SJW (900 mg/d for 6 weeks)              Citalopram (20 mg/d for 6 weeks)         CCMD-3               HAMD total score ≥18      HAMD, HAMA, clinical response, adverse events   60    2
  Li and Wei[@b40-ndt-12-1715]           Randomized, controlled                           People's Republic of China   Post-stroke depression              SJW (600 mg/d for 6 weeks)              Citalopram (20 mg/d for 6 weeks)         Unknown              HAMD total score ≥18      HAMD, HAMA, clinical response, adverse events   60    2
  Li[@b41-ndt-12-1715]                   Randomized, controlled                           People's Republic of China   Post-stroke depression              SJW (900 mg/d for 12 weeks)             Fluoxetine (20 mg/d for 12 weeks)        CCMD-3               Unknown                   HAMD, HAMA, clinical response, adverse events   158   2
  Tang et al[@b42-ndt-12-1715]           Randomized, controlled                           People's Republic of China   Depressive disorder                 SJW (600--900 mg/d for 8 weeks)         Sertraline (50--100 mg/d for 8 weeks)    CCMD-3               Unknown                   HAMD, HAMA, clinical response, adverse events   64    2
  Tan et al[@b43-ndt-12-1715]            Randomized, controlled                           People's Republic of China   Post-stroke depression              SJW (900 mg/d for 4 weeks)              Paroxetine (20 mg/d for 4 weeks)         CCMD                 Unknown                   Clinical response, adverse events               120   2
  Wang and Chen[@b45-ndt-12-1715]        Randomized, controlled                           People's Republic of China   Hypertension with depression        SJW (900 mg/d for 12 weeks)             Paroxetine (30 mg/d for 12 weeks)        Unknown              HAMD total score ≥18      HAMD, clinical response, adverse events         200   3

**Abbreviations:** AD, adverse events; CCMD, Chinese classification of mental disorders; CGI-I, clinical global impression-improvement; DSM, diagnostic and statistical manual of mental disorders; HAMA, Hamilton anxiety scale; HAMD, Hamilton rating scale for depression; HDRS-17, 17-item Hamilton depression scale; ICD, international classification of diseases; SJW, St John's Wort; SSRIs, selective serotonin reuptake inhibitors.
